Neuroendocrine Tumors: all 682 studies
Page 7 of 7. Open to participants first (163), then studies with results posted, then the rest; newest registration first within each.
- 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.Status unknownNCT01931488Phase 2
- EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective StudyStatus unknownNCT01902238Not applicable
- Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's PerspectiveCompletedNCT01873248Early Phase 1
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant DiseaseWithdrawnNCT01864070Phase 1
- Randomized Phase III of PRRT Versus InterferonWithdrawnNCT01860742Phase 3
- Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot StudyCompletedNCT01849523Not applicable
- Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine TumorCompletedNCT01845675Phase 2
- 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETsCompletedNCT01842165Phase 3
- Somatuline Predictive Factors in Acromegaly and NETCompletedNCT01840449
- Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014Active, not recruitingNCT01763554
- Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine TumorsTerminatedNCT01755182Phase 3
- TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT01747096Not applicable
- Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBGCompletedNCT01730417Phase 1
- 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine TumoursCompletedNCT01673906Phase 2
- Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsTerminatedNCT01648465Phase 2
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
- Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine TumorsCompletedNCT01603004
- Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsCompletedNCT01590199Phase 1
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
- A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal TumorsCompletedNCT01476592Not applicable
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic MetastasesCompletedNCT01469572Phase 1
- A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine TumorsCompletedNCT01456078Phase 2
- Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four HoursStatus unknownNCT01448083
- The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver MetastasesCompletedNCT01423734
- Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.CompletedNCT01398306
- Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal PancreatectomyCompletedNCT01384617Not applicable
- Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine TumorsStatus unknownNCT01381822Phase 1
- Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)CompletedNCT01364415Phase 1
- 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine TumorsCompletedNCT01338090
- Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine TumorCompletedNCT01324492Phase 1
- Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsCompletedNCT01263353Phase 1
- A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsCompletedNCT01262235Phase 1/2
- 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine NeoplasmsCompletedNCT01237457Phase 2
- A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of DiarrheaCompletedNCT01234168
- Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine TumorsTerminatedNCT01215578Phase 2
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT01203306Phase 2
- Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)Status unknownNCT01201096
- Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine TumorStatus unknownNCT01175096Phase 1/2
- Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic MalignanciesTerminatedNCT01163526
- B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
- Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine TumorCompletedNCT01099540Phase 2
- Combination Targeted Radiotherapy in Neuroendocrine TumorsCompletedNCT01099228Not applicable
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)WithdrawnNCT01048086Phase 2
- SwissNET - a Registry for Neuroendocrine Tumours in SwitzerlandTerminatedNCT01039922
- High Dose Somatostatin Analogues in Neuroendocrine TumorsCompletedNCT00990535Phase 2
- DOTA-TOC in Metastasized Neuroendocrine TumorsCompletedNCT00978211Phase 2
- Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau DiseaseCompletedNCT00970970
- 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine TumorsCompletedNCT00953394Phase 2
- Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT00942682Phase 1
- ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine TumorsStatus unknownNCT00851604
- Best Therapy for Patients With Neuroendocrine TumorsCompletedNCT00815620
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT00804336Phase 1
- Gastrointestinal Motility in Patients With Neuroendocrine TumorsCompletedNCT00789841
- Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00780663Phase 2
- Non Interventional Post Marketing Programme in Neuroendocrine TumoursCompletedNCT00747786
- A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine TumorsCompletedNCT00745381
- 11C-Acetate PET/CT Non-FDG-Avid TumorsStatus unknownNCT00687778
- Clinical and Pathologic Studies in Neuroendocrine TumorsWithdrawnNCT00657332
- Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsCompletedNCT00602082Phase 2
- Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine TumorsCompletedNCT00590343Phase 2
- Ga68-DOTA-NOC-PET Imaging of Neuroendocrine TumorsStatus unknownNCT00569738
- Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine TumorsTerminatedNCT00466856Phase 2
- Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine TumorsCompletedNCT00442533Phase 2/3
- Pemetrexed in Patients With Advanced Neuroendocrine TumorsCompletedNCT00424723Phase 2
- Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine TumoursCompletedNCT00326469Phase 2
- [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine TumoursTerminatedNCT00323076Phase 1/2
- SPECT/CT in Endocrine and Neuroendocrine TumorsCompletedNCT00230139Not applicable
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
- Effect of Oral 5-HTP Intake on Urinary 5-HIAA ExcretionTerminatedNCT00227136Phase 3
- Thalidomide in Combination With Temodar in Patients With Neuroendocrine TumorsCompletedNCT00165230Phase 2
- Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine TumorsCompletedNCT00137774Phase 2
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Treatment With SU11248 in Patients With Neuroendocrine TumorsCompletedNCT00056693Phase 2
- EPO906 in Carcinoid and Other Neuroendocrine TumorsCompletedNCT00050349Phase 2
- High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsCompletedNCT00037869Phase 3
- Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
- PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
- Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCompletedNCT00004922Phase 2
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNCT00003514Phase 2